[18F]AlF-RESCA-RT4 免疫 PET/CT 显像 Trop2 表达提升乳腺癌及转移灶诊断
本研究在回顾性免疫组化队列中分析乳腺癌各分子亚型 Trop2 表达,并以前瞻性 PET 显像队列评估新型 Trop2 靶向示踪剂 [18F]AlF-RESCA-RT4 对原发灶和转移灶的诊断效能,并与 18F-FDG PET/CT 比较。结果显示 Trop2 在乳腺癌各分子亚型中高表达且与临床病理特征无关,[18F]AlF-RESCA-RT4 摄取与 Trop2 表达强相关,对原发灶和淋巴结转移诊断敏感性、特异性高,对淋巴结转移特异性和准确性优于 18F-FDG,并检出更多骨转移灶。
要点
- Trop2 在乳腺癌各分子亚型中高表达,且与临床病理特征无显著相关。
- [18F]AlF-RESCA-RT4 摄取与肿瘤标本 Trop2 表达强相关(R²=0.7346)。
- 该示踪剂对淋巴结转移特异性和准确性优于 18F-FDG,并检出更多骨转移灶。
核心结论
- Trop2 在乳腺癌所有分子亚型中高表达且与临床病理特征无关。
- [18F]AlF-RESCA-RT4 免疫 PET/CT 对 Trop2 阳性乳腺癌具高敏感性和特异性,对淋巴结和骨转移诊断效能优于 18F-FDG PET/CT。
研究设计与样本
- 研究分析两个独立患者队列:回顾性免疫组化队列和前瞻性 PET 显像队列。
- 回顾性队列用组织芯片免疫组化检测 Trop2 表达,以 H-score(0-300)量化。
- 前瞻性显像研究纳入 35 例乳腺癌患者行 [18F]AlF-RESCA-RT4 免疫 PET/CT 检测原发灶和潜在转移灶,并用病理标本 Trop2 免疫组化染色与 PET 结果关联。
- 采用受试者工作特征曲线确定示踪剂诊断截断值。
- 对同时行 18F-FDG PET/CT 的 14 例患者进行亚组分析。
主要发现
- 回顾性免疫组化显示乳腺癌组织 Trop2 表达显著高于癌旁正常组织(P < 0.001),与临床病理特征无显著相关。
- 在进行的临床试验(NCT06715826)中,[18F]AlF-RESCA-RT4 摄取与原发和转移肿瘤标本 Trop2 表达水平强相关(R² = 0.7346,P < 0.001)。
- 原发肿瘤 SUVmax 截断值 2.66 时诊断敏感性 97.1%、特异性 93.1%(P < 0.001);淋巴结转移 SUVmax 截断值 1.74 时敏感性 88.2%、特异性 97.2%(P < 0.001)。
- 与 18F-FDG 相比,[18F]AlF-RESCA-RT4 对淋巴结转移特异性更高(100% vs. 94.67%,P = 0.004)、准确性更高(97.83% vs. 93.48%,P = 0.009),并检出更多骨转移灶(213 vs. 157)。
- [18F]AlF-RESCA-RT4 免疫 PET/CT 对大多数侵袭性癌种具良好诊断价值(神经内分泌肿瘤除外),并能有效区分肿瘤与炎性疾病。
关键数值与推荐
- 原发肿瘤诊断截断值:SUVmax 2.66。
- 淋巴结转移诊断截断值:SUVmax 1.74。
- 原发肿瘤诊断敏感性 97.1%、特异性 93.1%(P < 0.001)。
- 淋巴结转移诊断敏感性 88.2%、特异性 97.2%(P < 0.001)。
- 淋巴结转移诊断:特异性 100% vs. 94.67%(P = 0.004),准确性 97.83% vs. 93.48%(P = 0.009)。
临床怎么用
- 对乳腺癌患者可行 [18F]AlF-RESCA-RT4 免疫 PET/CT 无创评估 Trop2 表达,辅助诊断原发灶和转移灶。
- 该显像对淋巴结转移特异性和准确性优于 18F-FDG,并可检出更多骨转移灶,可用于分期评估。
- 原发灶 SUVmax 2.66、淋巴结转移 SUVmax 1.74 可作为诊断参考截断值。
- 该显像有助于区分肿瘤与炎性疾病,但对神经内分泌肿瘤诊断价值有限。
局限性
- 前瞻性显像队列样本量为 35 例,与 18F-FDG 对照的亚组仅 14 例。
- 研究为单中心前瞻性显像研究,结论需更大样本验证。
- 对神经内分泌肿瘤的诊断价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to evaluate human trophoblast cell surface antigen 2 (Trop2) expression across molecular subtypes of breast cancer and assess the diagnostic performance of a novel Trop2-targeted tracer, [18F]AlF-RESCA-RT4, compared with 18F-FDG PET/CT for patients with breast cancer. Methods: This study analyzed Trop2 expression across 2 independent patient cohorts: a retrospective immunohistochemistry cohort and a prospective PET imaging cohort. In the retrospective cohort, Trop2 expression was detected using immunohistochemistry on tissue microarrays and quantified using the H-score (0-300). In the prospective imaging study, 35 patients with breast cancer underwent [18F]AlF-RESCA-RT4 immuno-PET/CT imaging to detect primary lesions and potential metastases. Pathology specimens were subsequently used for Trop2 immunohistochemistry staining to correlate with PET findings. Receiver-operating-characteristic curves were used to determine the tracer's diagnostic cutoff values. A subgroup analysis was performed for 14 patients who also underwent 18F-FDG PET/CT imaging. Results: Retrospective immunohistochemistry results showed that Trop2 expression was significantly higher in breast tumor tissues than in adjacent normal tissues (P < 0.001), with no significant correlation with clinicopathologic features. In an ongoing clinical trial (NCT06715826), [18F]AlF-RESCA-RT4 uptake strongly correlated with Trop2 expression levels in the corresponding primary and metastatic tumor specimens (R 2 = 0.7346, P < 0.001). Cutoff values for the primary tumors (SUVmax, 2.66) and lymph node metastases (SUVmax, 1.74) showed high diagnostic sensitivity and specificity, with 97.1% and 93.1% (P < 0.001) for primary tumors and 88.2% and 97.2% (P < 0.001) for lymph node metastases, respectively. Compared with 18F-FDG, [18F]AlF-RESCA-RT4 demonstrated higher specificity (100% vs. 94.67%, P = 0.004) and accuracy (97.83% vs. 93.48%, P = 0.009) for lymph node metastases and detected more bone metastatic lesions (213 vs. 157). [18F]AlF-RESCA-RT4 immuno-PET/CT imaging demonstrated good diagnostic value for most invasive cancer types, except neuroendocrine tumors, and effectively differentiated tumors from inflammatory diseases. Conclusion: Trop2 was highly expressed across all molecular subtypes of breast cancer and was not correlated with clinicopathologic features. [18F]AlF-RESCA-RT4 immuno-PET/CT is a highly sensitive and specific imaging tool for Trop2-positive breast cancer, offering superior diagnostic performance for nodal and bone metastases compared with 18F-FDG PET/CT.
引用
- Jia W, Yan T, An S, et al. Immuno-PET/CT Imaging of Trop2 Expression with [18F]AlF-RESCA-RT4 Enhances Diagnosis of Breast Cancers and the Metastases. J Nucl Med. 2026. PMID: 42134979. doi:10.2967/jnumed.125.271093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。